Advancements In Targeted Therapy for Acute Myeloid Leukemia: Insights from Oxford Hematology Oncology Research | [International Journal of Membrane Science and Technology • 2024]

Author(s):

1. Hashim Mahmood: University College of Medicine and Dentistry Lahore, Pakistan

2. Fathima Farzana: General practitioner, GSM Medical Center LLC

3. Dhoha Mohamed Ahmed Alsalmi: University of Sharjah.

4. Haya Ashraf: Shifa College of Medicine/Shifa International Hospital Islamabad Pakistan

5. Aiza Bint-e-Shafqat: Bahria International Hospital

6. Rawda Ahmed Mehanna: Clinical teaching assistant, clinical sciences department, Dubai Medical collage for Girls, Dubai

7. Maha hasan: Medcare hospital UAE

8. Mais Abd aziz Mohammad: Medcare hospital UAE

9. Ashtar kariem: Post Graduate Clinical Trainee under SGH

Abstract:

Acute Myeloid Leukemia (AML) is a heterogeneous and aggressive hematological malignancy, with limited treatment options and poor patient outcomes. Recent advancements in targeted therapy have shown promise in improving patient survival and quality of life. This review article provides an overview of the latest developments in targeted therapy for AML, highlighting the most impactful research findings from Oxford Hematology Oncology Research. We discuss the emerging roles of novel agents, such as FLT3 inhibitors and IDH1/2 mutants, and their potential for combination therapies. Additionally, we explore the current challenges and future directions in AML research, emphasizing the need for personalized medicine approaches and innovative clinical trial designs. Our insights aim to inform and inspire future research directions in AML targeted therapy, ultimately improving patient care and outcomes.

Page(s): 680-688

DOI: 10.15379/ijmst.v11i1.3753

Published: Journal: International Journal of Membrane Science and Technology, Volume: 11, Issue: 1, Year: 2024

Keywords:

Acute myeloid leukemia AML , targeted therapy , Personalized Medicine , FLT3 Inhibitors , Novel Agents , Hematological Malignancy , IDH12 Mutants , Oxford Hematology Oncology Research , Combination Therapies

References:

[1] Tallman M. Prognostic .2018 .Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia. J Natl Compr Canc Netw, 0050(5S) : 656-659.

[2] Wingelhofer B,Maurer B,Heyes EC .2018 .Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia, 10(5) : 1135-1146.

[3] Short NJ,Nguyen D .2023 .Published 2023 Sep 11. Blood Cancer J, 10(1) : 142.

[4] Weiss RD,Potter JS,Griffin ML .2015 .Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend, 02 : 112-119.

[5] Takahashi S. Combination .2023 .Published 2023 May 24. Hematol Rep, 10(2) : 331-346.

[6] .2024 .[6] Targeted therapy drugs for Acute myeloid leukemia (AML) [Online]. html [27 Jun, : .

[7] Larrosa-Garcia M.,Baer M.R. . .FLT3 inhibitors in acute myeloid leukemia: Current status and Future Directions, Molecular cancer therapeutics. , : .

[8] Chen X. .2024 .Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: A systematic review and meta-analysis - clinical epigenetics, BioMed Central. com/articles/10.1186/s13148-023-01529-2 (Accessed: 28 June, : .

[9] Ma S.,Brander D.,Seymour J. .2024 .-venetoclax-plus-rituximab-for-relapsed (. Accessed: 28 June, : .

[10] Garcia J.,Wei A.,Borate U.,Safety-Efficacy- U.,-PatientReported- U. .2024 .Safety, efficacy, and patient-reported outcomes of Venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: A phase 1B study | blood | american Society of Hematology. (Accessed: 28 June, : .

[11] Iyer S. G.,Stanchina M.,Bradley T. J.,Watts J. .2022 .Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date. Cancer management and research, 14 : 2267-2272.

[12] Cortes J. E.,Heidel F. H.,Hellmann A.,Fiedler W.,Smith B. D.,Robak T.,Montesinos P.,Pollyea D. A.,Ottmann P.,Ma O.,Shaik M. N.,Laird A. D.,Zeremski M.,'Connell O,Chan A.,Heuser G.,M. G. .2019 .Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia, 33(2) : 379-389.

[13] .2020 .Comparative Efficacy of Targeted Therapies in Old Unfit Intermediate to High-risk Patients with Acute Myeloid Leukemia: A Meta-analysis of Comparative Studies. , : .

[14] American Cancer Society. .2024 .Targeted therapy for Acute Myeloid Leukemia. html (reviewed on 28/06/, : .

[15] .2024 .. [15] Oxford Hematology Oncology Research, : .

[16] Estey E.,Döhner H. .2006 .Acute myeloid leukemia. The Lancet, 368(9550) : 1894-1907.

[17] National Cancer Institute. .2020 .-aml-treatment-pdq. , : .

[18] Chen X,Xing H,Xie X,Kou L,Li J,Li Y .2023 .Published 2023 Jul 11. Clin Epigenetics, 10(1) : 113.

[19] Molica M,Perrone S,Federico V,Alati C,Molica S,Rossi M. .2023 .Published 2023 Dec 22. Cancers (Basel), 10(1) : 73.

[20] Lin T,Liu D,Guan Z .2024 .Published 2024 Apr 9. Heliyon, 10(8) : e29382.

[21] Atilla E,Benabdellah K.,The Black Hole: CAR T Cell K. .2023 .Published 2023 May 11. Cancers (Basel), 10(10) : 2713.

[22] Damiani D,Tiribelli M. Checkpoint .2023 .Published 2023 Jun 15. Biomedicines, 10(6) : 1724.

[23] DiNardo CD,Cortes JE .2015 .. , 981527 : .

[24] .2015 .treatment for acute myelogenous leukemia. Expert Opin Pharmacother, 16(1) : 95-106.

[25] Bazinet A,Kantarjian HM .2022 .Moving toward individualized target-based therapies in acute myeloid leukemia. Ann Oncol, 11(2) : 141-151.

Citations

Downloads

Views